Jazz Pharmaceuticals plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Jazz Pharmaceuticals plc (JAZZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $134.51 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $134.51, a 16.15% increase from fiscal 2024.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $115.81, a 3.72% decline from fiscal 2023.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $120.29, a 12.67% increase from fiscal 2022.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $106.76, a 6.62% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $134.51 10-K · filed 2026-02-24 |
| 2024-12-31 | $115.81 10-K · filed 2025-02-26 |
| 2023-12-31 | $120.29 10-K · filed 2024-02-28 |
| 2022-12-31 | $106.76 10-K · filed 2023-03-01 |
| 2021-12-31 | $114.33 10-K · filed 2022-03-01 |
| 2020-12-31 | $111.47 10-K · filed 2021-02-23 |
| 2019-12-31 | $90.27 10-K · filed 2020-02-25 |
| 2018-12-31 | $107.45 10-K · filed 2019-02-26 |
| 2017-12-31 | $53.03 10-K · filed 2018-02-27 |
| 2016-12-31 | $42.35 10-K · filed 2017-02-28 |
| 2015-12-31 | $45.04 10-K · filed 2016-02-23 |
| 2014-12-31 | $36.33 10-K · filed 2015-02-24 |
| 2013-12-31 | $23.13 10-K · filed 2014-02-25 |
| 2012-12-31 | $15.05 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |